Content continues after advertisement

Research Note: Antibody Response to Feline Panleukopenia Virus Vaccination

Sign in to Print/View PDF

The goal of this study* was to evaluate the antibody response in healthy adult cats within 28 days of feline panleukopenia virus (FPV) vaccination and evaluate factors associated with adequate antibody response. Results show that 64.3% of 112 cats had antibody titers of ≥1:40 on day 0 and therefore were likely protected against FPV prior to vaccination. An adequate response to vaccination, defined as a 4-fold titer increase, was found in 48.3% of cats. Adequate vaccination response was associated with a lack of previous vaccination, lower day 0 antibody titer (<1:40), and the domestic shorthair breed. Because cats with higher prevaccination titers (ie, ≥1:40) had inadequate antibody responses to revaccination, the authors recommend measuring FPV antibody titers prior to vaccination.

*This study was funded and supported by Merial.


For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.


Clinician's Brief:
The Podcast
Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2022 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Terms & Conditions | DMCA Copyright | Privacy Policy | Acceptable Use Policy